Omnicell receives notification from NASDAQ OMX Group for noncompliance with Nasdaq Listing Rule

As indicated in a Form 8-K filed with the SEC on March 20, 2015, Omnicell, Inc. received a written notification from the NASDAQ OMX Group, Inc. on March 18, 2015, indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) for continued listing, due to the delay in filing its Annual Report on Form 10-K for the period ended December 31, 2014 beyond the extended filing due date of March 17, 2015.



from The Medical News http://ift.tt/1GiZp2d